144 related articles for article (PubMed ID: 15845856)
1. Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure.
Lockman PR; McAfee G; Geldenhuys WJ; Van der Schyf CJ; Abbruscato TJ; Allen DD
J Pharmacol Exp Ther; 2005 Aug; 314(2):636-42. PubMed ID: 15845856
[TBL] [Abstract][Full Text] [Related]
2. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.
Levi M; Dempsey DA; Benowitz NL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):23-34. PubMed ID: 17206525
[TBL] [Abstract][Full Text] [Related]
3. Nicotine and cotinine increases the brain penetration of saquinavir in rat.
Manda VK; Mittapalli RK; Bohn KA; Adkins CE; Lockman PR
J Neurochem; 2010 Dec; 115(6):1495-507. PubMed ID: 20950334
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of nicotine and its metabolites I. Model development.
Levi M; Dempsey DA; Benowitz NL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):5-21. PubMed ID: 17206524
[TBL] [Abstract][Full Text] [Related]
5. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
Nakajima M; Yamagishi S; Yamamoto H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2000 Jan; 67(1):57-69. PubMed ID: 10668854
[TBL] [Abstract][Full Text] [Related]
6. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.
Hukkanen J; Jacob P; Benowitz NL
Clin Pharmacol Ther; 2006 Nov; 80(5):522-30. PubMed ID: 17112808
[TBL] [Abstract][Full Text] [Related]
7. Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine.
Lockman PR; Van der Schyf CJ; Abbruscato TJ; Allen DD
J Neurochem; 2005 Jul; 94(1):37-44. PubMed ID: 15953347
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
Schoedel KA; Sellers EM; Palmour R; Tyndale RF
Mol Pharmacol; 2003 Jan; 63(1):96-104. PubMed ID: 12488541
[TBL] [Abstract][Full Text] [Related]
9. (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner.
Dwoskin LP; Teng L; Buxton ST; Crooks PA
J Pharmacol Exp Ther; 1999 Mar; 288(3):905-11. PubMed ID: 10027825
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
Mwenifumbo JC; Lessov-Schlaggar CN; Zhou Q; Krasnow RE; Swan GE; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2008 Jan; 83(1):115-21. PubMed ID: 17522595
[TBL] [Abstract][Full Text] [Related]
11. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells.
Abbruscato TJ; Lopez SP; Mark KS; Hawkins BT; Davis TP
J Pharm Sci; 2002 Dec; 91(12):2525-38. PubMed ID: 12434396
[TBL] [Abstract][Full Text] [Related]
12. Nicotine metabolism and elimination kinetics in newborns.
Dempsey D; Jacob P; Benowitz NL
Clin Pharmacol Ther; 2000 May; 67(5):458-65. PubMed ID: 10824624
[TBL] [Abstract][Full Text] [Related]
13. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
14. Molecular orbital calculations and nicotine metabolism: a rationale for experimentally observed metabolite ratios.
Lewis DF; Gorrod JW
Drug Metabol Drug Interact; 2002; 19(1):29-39. PubMed ID: 12222752
[TBL] [Abstract][Full Text] [Related]
15. Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine.
Hukkanen J; Gourlay SG; Kenkare S; Benowitz NL
Clin Pharmacol Ther; 2005 Mar; 77(3):159-69. PubMed ID: 15735610
[TBL] [Abstract][Full Text] [Related]
16. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
17. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
Mwenifumbo JC; Tyndale RF
Pharmacogenomics; 2007 Oct; 8(10):1385-402. PubMed ID: 17979512
[TBL] [Abstract][Full Text] [Related]
18. Nicotine is more efficient than cotinine at passing the blood-brain barrier in rats.
Riah O; Courrière P; Dousset JC; Todeschi N; Labat C
Cell Mol Neurobiol; 1998 Jun; 18(3):311-8. PubMed ID: 9590561
[TBL] [Abstract][Full Text] [Related]
19. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.
von Weymarn LB; Brown KM; Murphy SE
J Pharmacol Exp Ther; 2006 Jan; 316(1):295-303. PubMed ID: 16188955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
